Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjunct agents for bleeding.

Massimo Franchini1, Pier Mannuccio Mannucci

  • 1aDepartment of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova bScientific Direction, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, Italy.

Current Opinion in Hematology
|August 28, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood safety and zoonotic emerging pathogens: now it's the turn of Zika virus!

Blood transfusion = Trasfusione del sangue·2015
Same author

Association between particulate air pollution and venous thromboembolism: A systematic literature review.

European journal of internal medicine·2015
Same author

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

Seminars in thrombosis and hemostasis·2015
Same author

Correlation between ABO Blood Group, and Conventional Hematological and Metabolic Parameters in Blood Donors.

Seminars in thrombosis and hemostasis·2015
Same author

Alcohol consumption and venous thromboembolism: friend or foe?

Internal and emergency medicine·2015
Same author

Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature.

Seminars in thrombosis and hemostasis·2015
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Tranexamic acid shows promise for treating coagulopathy in critical bleeding. Early administration in trauma patients improved survival, but more research on prohemostatic agents is needed.

Area of Science:

  • Critical care medicine
  • Hematology
  • Pharmacology

Background:

  • Coagulopathy is a life-threatening complication in critical bleeding.
  • Hemostatic agents are used to manage bleeding disorders.
  • Recent clinical trials have investigated various agents for treating coagulopathy.

Purpose of the Study:

  • To review recent clinical trials on hemostatic agents for critical bleeding.
  • To evaluate antifibrinolytic agents, desmopressin, recombinant activated factor VII, fibrinogen, and prothrombin complex concentrates.
  • To identify promising therapeutic options for coagulopathy.

Main Methods:

  • Systematic review of clinical trials.
  • Evaluation of hemostatic agents including antifibrinolytics, desmopressin, rFVIIa, fibrinogen, and PCCs.

Related Experiment Videos

  • Analysis of data on safety and efficacy in critical bleeding.

    • Main Results:

    • Tranexamic acid is a highly promising agent.
    • A recent randomized trial demonstrated improved survival with early tranexamic acid administration in trauma-induced coagulopathy.
    • Other agents are also under investigation.

    Conclusions:

    • Preliminary data suggest a therapeutic role for prohemostatic pharmacologic approaches.
    • Further randomized controlled trials are required.
    • The safety and efficacy of these agents in critical bleeding need comprehensive assessment.